# Comparison of Platelet Inhibition With Adjunctive Cilostazol Versus High Maintenance-Dose Clopidogrel According to Hepatic Cytochrome 2C19 Allele (CYP2C19) Polymorphism

> **NCT00891670** · PHASE3 · UNKNOWN · sponsor: **Gyeongsang National University Hospital** · enrollment: 80 (estimated)

## Conditions studied

- Coronary Artery Stenosis
- Maximal Platelet Aggregation
- Late Platelet Aggregation
- High Post-Treatment Platelet Reactivity

## Interventions

- **DRUG:** cilostazol
- **DRUG:** clopidogrel
- **DRUG:** aspirin

## Key facts

- **NCT ID:** NCT00891670
- **Lead sponsor:** Gyeongsang National University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2009-05
- **Primary completion:** 2009-06
- **Final completion:** 2009-07
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2009-05-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00891670

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00891670, "Comparison of Platelet Inhibition With Adjunctive Cilostazol Versus High Maintenance-Dose Clopidogrel According to Hepatic Cytochrome 2C19 Allele (CYP2C19) Polymorphism". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00891670. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*